A leading ophthalmology company leveraging "Santen Commercial Excellence*1" to earn the trust of patients and the ophthalmic community worldwide
Continuously pursue optimal eye care from a patient perspective, maximizing product value through promotion of appropriate treatment concepts and care, and providing optimal care to patients through strong collaboration with stakeholders in each market
Deeply understand patients' unmet needs and medical challenges, utilizing our extensive ophthalmic expertise and open collaboration to deliver innovative products for untreated diseases and products that shift the paradigm for existing standard treatments
The ophthalmology market is expected to continue to grow against a backdrop of significant unmet needs. As a global pharmaceutical company specializing in ophthalmology, Santen will leverage its strengths in product origination and value maximization to further enhance “Santen Commercial Excellence”. Through this initiative, Santen will provide optimal eye care treatments to more people by developing and launching products that address unmet needs in a broad range of ophthalmic diseases.
Strengthen Santen's business model across all regions, build market-leader reputation and establish foundations for sustainable growth
Sales revenue | 400 billion yen |
---|---|
Core operating profit | 80 billion yen (EBITDA:90 billion yen) *2 |
ROE | Over 14% |
EPS Growth rate | Double-digit growth *3 (EPS: 160 yen or more) |
Shareholder returns |
|
In addition to cash generated from operations, the company will maximize investment capacity by reducing working capital, utilizing surplus funds within the group, and raising funds in line with capital needs. As growth investments for the future, the company will prioritize investments in facility upgrades to expand production capacity and in research and development and business development to create innovation. Regarding shareholder returns, the company will continue to provide cash returns to shareholders through its progressive dividend system, maintaining the current minimum annual dividend of 38 yen and increasing dividends in line with profit growth. Santen will optimize its capital base through flexible share buybacks with the aim of improving ROE and EPS.
To contribute to society and achieve sustainable growth, Santen will vigorously promote the following 13 materialities (most important materialities*5 ).
Sustainable growth of society and business
Strengthen business foundation
Specific efforts and other details will be disclosed through Santen’s corporate website and other channels in the future.
Apr 13, 2023 | |
---|---|
May 19, 2021 | |
Jun 05, 2018 | |
Aug 06, 2014 | |
May 11, 2011 | |
Jul 25, 2006 | |
Feb 20, 2003 |